These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35227606)

  • 1. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States.
    Guzauskas GF; Jiang S; Garbett S; Zhou Z; Spencer SJ; Snyder SR; Graves JA; Williams MS; Hao J; Peterson JF; Veenstra DL
    Genet Med; 2022 May; 24(5):1017-1026. PubMed ID: 35227606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.
    Pastorino R; Basile M; Tognetto A; Di Marco M; Grossi A; Lucci-Cordisco E; Scaldaferri F; De Censi A; Federici A; Villari P; Genuardi M; Ricciardi W; Boccia S
    PLoS One; 2020; 15(7):e0235038. PubMed ID: 32609729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
    Cenin DR; Naber SK; Lansdorp-Vogelaar I; Jenkins MA; Buchanan DD; Preen DB; Ee HC; O'Leary P
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1737-1744. PubMed ID: 29645364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
    Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
    J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives.
    Salikhanov I; Heinimann K; Chappuis P; Buerki N; Graffeo R; Heinzelmann V; Rabaglio M; Taborelli M; Wieser S; Katapodi MC
    J Med Genet; 2022 Sep; 59(9):924-930. PubMed ID: 34782441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
    Snowsill T; Huxley N; Hoyle M; Jones-Hughes T; Coelho H; Cooper C; Frayling I; Hyde C
    Health Technol Assess; 2014 Sep; 18(58):1-406. PubMed ID: 25244061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.
    Guzauskas GF; Garbett S; Zhou Z; Schildcrout JS; Graves JA; Williams MS; Hao J; Jones LK; Spencer SJ; Jiang S; Veenstra DL; Peterson JF
    Ann Intern Med; 2023 May; 176(5):585-595. PubMed ID: 37155986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.
    Gallego CJ; Shirts BH; Bennette CS; Guzauskas G; Amendola LM; Horike-Pyne M; Hisama FM; Pritchard CC; Grady WM; Burke W; Jarvik GP; Veenstra DL
    J Clin Oncol; 2015 Jun; 33(18):2084-91. PubMed ID: 25940718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age.
    Leenen CH; Goverde A; de Bekker-Grob EW; Wagner A; van Lier MG; Spaander MC; Bruno MJ; Tops CM; van den Ouweland AM; Dubbink HJ; Kuipers EJ; Dinjens WN; van Leerdam ME; Steyerberg EW
    Genet Med; 2016 Oct; 18(10):966-73. PubMed ID: 26938782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome.
    Kang YJ; Killen J; Caruana M; Simms K; Taylor N; Frayling IM; Snowsill T; Huxley N; Coupe VM; Hughes S; Freeman V; Boussioutas A; Trainer AH; Ward RL; Mitchell G; Macrae FA; Canfell K
    Med J Aust; 2020 Feb; 212(2):72-81. PubMed ID: 31595523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan.
    Chen YE; Kao SS; Chung RH
    PLoS One; 2016; 11(8):e0160599. PubMed ID: 27482709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 15. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.
    Sie AS; Mensenkamp AR; Adang EMM; Ligtenberg MJL; Hoogerbrugge N
    Ann Oncol; 2014 Oct; 25(10):2001-2007. PubMed ID: 25081898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting.
    Snowsill TM; Ryan NAJ; Crosbie EJ; Frayling IM; Evans DG; Hyde CJ
    PLoS One; 2019; 14(8):e0221419. PubMed ID: 31469860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.
    Di Marco M; DAndrea E; Panic N; Baccolini V; Migliara G; Marzuillo C; De Vito C; Pastorino R; Boccia S; Villari P
    Genet Med; 2018 Oct; 20(10):1131-1144. PubMed ID: 29300371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome.
    Wang G; Kuppermann M; Kim B; Phillips KA; Ladabaum U
    Am J Manag Care; 2012 May; 18(5):e179-85. PubMed ID: 22694112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of screening strategies for Lynch syndrome.
    Barzi A; Sadeghi S; Kattan MW; Meropol NJ
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined population genomic screening for three high-risk conditions in Australia: a modelling study.
    Lacaze P; Marquina C; Tiller J; Brotchie A; Kang YJ; Merritt MA; Green RC; Watts GF; Nowak KJ; Manchanda R; Canfell K; James P; Winship I; McNeil JJ; Ademi Z
    EClinicalMedicine; 2023 Dec; 66():102297. PubMed ID: 38192593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.